Literature DB >> 9228279

The 26S-proteasome: regulation and substrate recognition.

S Dawson1, R Hastings, K Takayanagi, S Reynolds, P Løw, M Billett, R J Mayer.   

Abstract

There is extensive reprogramming of the ATPase regulators of the 26S proteasome before the programmed elimination of the abdominal intersegmental muscles (ISM) after eclosion in Manduca sexta [1]. This extensive ATPase reprogramming only occurs in ISM which are destined to die and not in flight muscle (FM). The MS73 ATPase also increases in the proleg retractor muscles which die at a developmentally different stage to ISM. The non-ATPase regulator S5a shows a similar increase to the ATPase regulators. We have cloned the Manduca SUG2 ATPase and shown that this ATPase is a component of the 26S proteasome. This ATPase shows a similar increase in concentration to the other ATPases in 26S proteasomes before muscle death. The SUG2 ATPase is also associated with other smaller complexes besides the 26S proteasome which act as activators of the 26S proteasome. Finally, in a yeast two-hybrid genetic screen we have identified a protein in human brain which interacts with the MS73 ATPase (and human S6). The interacting protein contains 6 ankyrin repeats and is co-immunoprecipitated with anti-MS73 antiserum after in vitro transcription/translation. The ankyrin repeat protein may interact with the MS73 ATPase as part of the substrate recognition process by the 26S proteasome. Many proteins degraded by the 26S proteasome contain ankyrin repeats, e.g. IkB and some cyclins: binding through ankyrin repeats to an ATPase regulator may complement protein ubiquitination and S5a binding as recognition signals by the 26S proteasome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9228279     DOI: 10.1023/a:1006800522814

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

1.  Specific developmental changes in the regulatory subunits of the 26 S proteasome in intersegmental muscles preceding eclosion in Manduca sexta.

Authors:  K Takayanagi; S Dawson; S E Reynolds; R J Mayer
Journal:  Biochem Biophys Res Commun       Date:  1996-11-12       Impact factor: 3.575

2.  Expression of a 26S proteasome ATPase subunit, MS73, in muscles that undergo developmentally programmed cell death, and its control by ecdysteroid hormones in the insect Manduca sexta.

Authors:  P Löw; K Bussell; S P Dawson; M A Billett; R J Mayer; S E Reynolds
Journal:  FEBS Lett       Date:  1997-01-06       Impact factor: 4.124

3.  The multiubiquitin-chain-binding protein Mcb1 is a component of the 26S proteasome in Saccharomyces cerevisiae and plays a nonessential, substrate-specific role in protein turnover.

Authors:  S van Nocker; S Sadis; D M Rubin; M Glickman; H Fu; O Coux; I Wefes; D Finley; R D Vierstra
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

4.  A protein related to a proteasomal subunit binds to the intracellular domain of the p55 TNF receptor upstream to its 'death domain'.

Authors:  M P Boldin; I L Mett; D Wallach
Journal:  FEBS Lett       Date:  1995-06-19       Impact factor: 4.124

5.  Developmental changes of the 26 S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death.

Authors:  S P Dawson; J E Arnold; N J Mayer; S E Reynolds; M A Billett; C Gordon; L Colleaux; P M Kloetzel; K Tanaka; R J Mayer
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

6.  Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis.

Authors:  A Takahashi; E S Alnemri; Y A Lazebnik; T Fernandes-Alnemri; G Litwack; R D Moir; R D Goldman; G G Poirier; S H Kaufmann; W C Earnshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons.

Authors:  R Sadoul; P A Fernandez; A L Quiquerez; I Martinou; M Maki; M Schröter; J D Becherer; M Irmler; J Tschopp; J C Martinou
Journal:  EMBO J       Date:  1996-08-01       Impact factor: 11.598

8.  Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination.

Authors:  Y Murakami; S Matsufuji; T Kameji; S Hayashi; K Igarashi; T Tamura; K Tanaka; A Ichihara
Journal:  Nature       Date:  1992-12-10       Impact factor: 49.962

9.  Coordinated induction of the ubiquitin conjugation pathway accompanies the developmentally programmed death of insect skeletal muscle.

Authors:  A L Haas; O Baboshina; B Williams; L M Schwartz
Journal:  J Biol Chem       Date:  1995-04-21       Impact factor: 5.157

10.  The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme.

Authors:  J Yuan; S Shaham; S Ledoux; H M Ellis; H R Horvitz
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  5 in total

1.  Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1.

Authors:  K Su; X Yang; M D Roos; A J Paterson; J E Kudlow
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

Review 2.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

Authors:  Karine Breckpot; David Escors
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-12       Impact factor: 2.895

3.  Upregulation of PSMD10 caused by the JMJD2A histone demethylase.

Authors:  Tae-Dong Kim; Sangphil Oh; Stan A Lightfoot; Sook Shin; Jonathan D Wren; Ralf Janknecht
Journal:  Int J Clin Exp Med       Date:  2016-06-30

4.  Vimentin and PSF act in concert to regulate IbeA+ E. coli K1 induced activation and nuclear translocation of NF-κB in human brain endothelial cells.

Authors:  Feng Chi; Tao Bo; Chun-Hua Wu; Ambrose Jong; Sheng-He Huang
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

5.  Targeting lentiviral vectors for cancer immunotherapy.

Authors:  Frederick Arce; Karine Breckpot; Mary Collins; David Escors
Journal:  Curr Cancer Ther Rev       Date:  2011-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.